Interrupted therapy
Top Cited Papers
- 26 August 2003
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (4) , 551-554
- https://doi.org/10.1212/01.wnl.0000078885.05053.7d
Abstract
A retrospective chart review of patients in British Columbia with multiple sclerosis prescribed β-interferon (IFNβ) between 1995 and 2001 was carried out to investigate reasons for the interruption of therapy. The highest proportion of interruptions (76/281; 27%) occurred in the first 6 months. The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%). Gender, disability, and disease duration were identified as factors influencing interruption of IFNβ therapy.Keywords
This publication has 7 references indexed in Scilit:
- Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]Neurology, 2002
- ‘Gentle caring experience’Health & Place, 2001
- Multiple sclerosisNeurology, 1999
- Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatmentMultiple Sclerosis Journal, 1996
- Management of patients receiving interferon beta-1b for multiple sclerosisNeurology, 1996
- The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trialNeurology, 1994
- Prevalence of Multiple Sclerosis in British ColumbiaCanadian Journal of Neurological Sciences, 1986